Skip to main content

FTXH

ETF
—
—

Performance overview

FTXH Price
Price Chart

Forward-looking statistics

Beta
0.51
Risk
13.57%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Fund Profile

The fund will normally invest at least 90% of its net assets (including investment borrowings) in the securities that comprise the index. The index is designed to provide exposure to U.S. companies comprising the pharmaceutical sector that have been selected based upon their liquidity and ranking. It is non-diversified.

Fund info

The fund will normally invest at least 90% of its net assets (including investment borrowings) in the securities that comprise the index. The index is designed to provide exposure to U.S. companies comprising the pharmaceutical sector that have been selected based upon their liquidity and ranking. It is non-diversified.

Investing methodPassively Managed
DiversifiedNo
Expense ratio0.60%
Asset classUnknown

Company info

Sector—
Industry—
Website—
AUM—

Security info

ExchangeNASDAQ
Type of shareN/A
Earnings per share (EPS)—
Dividend per share$0.36
Revenue per share—
Avg trading volume (30 day)$271K
Avg trading volume (10 day)$688K
Put-call ratioN/A

Macro factor sensitivity

Growth+0.3
Credit+2.3
Liquidity-0.0
Inflation-1.4
Commodities-0.1
Interest Rates-1.0

Upcoming events

Next earnings day—
Next dividend day—
Ex. dividend dayJune 26, 2025

News

A Look at Pharma ETFs After Strong Q1 Earnings

Many pharma bigwigs reported solid results, with some beating on earnings or revenues or both.

Zacks Investment Research (May 8, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free